Neurogene (NGNE) Total Non-Current Liabilities (2013 - 2026)

Neurogene (NGNE) has 12 years of Total Non-Current Liabilities data on file, last reported at $25.4 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 8.11% year-over-year to $25.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.4 million (up 8.11% YoY) and the FY2025 annual result came in at $23.7 million, down 3.94% from the prior year.
• Total Non-Current Liabilities rose to $25.4 million in Q1 2026, from $23.7 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $36.3 million in Q4 2023 to a low of $10.6 million in Q4 2022.
• A 5-year average of $24.2 million and a median of $24.4 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities surged 241.66% — and 2024, when it tumbled 32.22%.
• Tracing NGNE's Total Non-Current Liabilities over 5 years: stood at $10.6 million in 2022, then surged by 241.66% to $36.3 million in 2023, then plunged by 32.22% to $24.6 million in 2024, then decreased by 3.94% to $23.7 million in 2025, then grew by 7.15% to $25.4 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $25.4 million (Q1 2026), $23.7 million (Q4 2025), and $22.2 million (Q3 2025), per Business Quant data.